INT105270

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 25
Total Number 27
Disease Relevance 11.49
Pain Relevance 1.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) plasma membrane (KDR)
nucleus (KDR) cytoplasm (KDR)
Anatomy Link Frequency
plasma 3
blood 1
hepatocyte 1
arm 1
MCF-7 1
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 22 96.80 Very High Very High Very High
Bioavailability 3 96.16 Very High Very High Very High
rheumatoid arthritis 5 87.60 High High
cytokine 66 86.80 High High
cINOD 14 83.36 Quite High
Inflammation 185 82.64 Quite High
Pain 9 82.32 Quite High
adenocard 1 81.44 Quite High
metalloproteinase 43 78.40 Quite High
opiate 3 75.00 Quite High
Disease Link Frequency Relevance Heat
Cancer 383 100.00 Very High Very High Very High
Necrosis 20 100.00 Very High Very High Very High
Leukemia 16 99.84 Very High Very High Very High
Coronary Artery Disease 164 99.78 Very High Very High Very High
Disease 157 99.16 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 4 98.96 Very High Very High Very High
Myocardial Infarction 92 98.60 Very High Very High Very High
Renal Cancer 73 98.52 Very High Very High Very High
Acute Coronary Syndrome 16 97.94 Very High Very High Very High
Cv Unclassified Under Development 34 94.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In 25 control subjects, 65 patients with coronary artery disease (CAD; 40 stable CAD, 25 acute coronary syndrome/acute myocardial infarction (ACS)), EPC were quantified using the following approach: Whole blood was incubated with CD45, KDR, and CD34.
Positive_regulation (incubated) of KDR in blood associated with acute coronary syndrome, coronary artery disease and myocardial infarction
1) Confidence 0.49 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2972200 Disease Relevance 0.86 Pain Relevance 0
SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor.
Positive_regulation (stimulation) of KDR
2) Confidence 0.49 Published 2002 Journal Clin. Cancer Res. Section Abstract Doc Link 12231519 Disease Relevance 0.22 Pain Relevance 0.05
Confirming our previous results, the 4-week de-novo treatment of atorvastatin in stable CAD evoked an increase only of CD45dimCD34+KDR+ EPC, confirming our previous study [24].
Positive_regulation (increase) of KDR associated with coronary artery disease
3) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2972200 Disease Relevance 0.58 Pain Relevance 0
Augmentation of both CD133 and CD34 cells in circulation was observed, as well as KDR-1+/CD34+ EPC capable of forming endothelial colonies.
Positive_regulation (Augmentation) of KDR
4) Confidence 0.42 Published 2010 Journal J Transl Med Section Body Doc Link PMC2862021 Disease Relevance 0.24 Pain Relevance 0
There is also justification for beginning investigations into dynamic regulation of receptor internalization, in particular for VEGFR2: VEGF-induction of VEGFR2 internalization has been shown in various studies as receptor tyrosine kinase (RTK) autophosphorylation-, dynamin-, clathrin- and VEGFR1-mediated processes [154]–[157].
Positive_regulation (induction) of VEGFR2
5) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Lowering NRP1's affinity for VEGF165 over two orders of magnitude – Kd(V165,N) from 200 pM to 25 nM –caused only opposing changes of up to 0.3% in the VEGF-bound fractional occupancies of VEGFR1 and VEGFR2 (Fig. 6D).
Positive_regulation (occupancies) of VEGFR2
6) Confidence 0.41 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
In a second study, a 4-week de-novo treatment of atorvastatin in stable CAD evoked an increase only of CD45dimCD34+KDR+ EPC (p<0.05).
Positive_regulation (increase) of KDR associated with coronary artery disease
7) Confidence 0.40 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2972200 Disease Relevance 0.84 Pain Relevance 0
Jie et al analysed the number of circulating CD34+/KDR+ EPCs in healthy subjects aged from 1 to 81 years old, and an inverse relationship with age was observed [10].
Positive_regulation (circulating) of KDR
8) Confidence 0.38 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2834645 Disease Relevance 0.76 Pain Relevance 0
On the other hand, the overall rise in “pro-angiogenic potential”, as represented by ligated VEGFR2 complexes, can be explained by NRP1's role as a co-receptor in presenting NRP1-bound VEGF165 to VEGFR2, as well as in stabilizing VEGF165-VEGFR2 through their triplet configuration.
Positive_regulation (stabilizing) of VEGFR2
9) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Particularly relevant is the latter process of regulation through VEGFR1-VEGFR2 crosstalk, which possibly presents an opportunity for sVEGFR1, as a VEGFR1 competitor, to moderate VEGFR2 activation and internalization.
Positive_regulation (activation) of VEGFR2
10) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
We observed maximal increases (almost doubling) of CD34+ KDR+ cells in PBMC occurring at day 7 of supplementation, whereas peak CFU-E activity occurred at day 2.
Positive_regulation (increases) of KDR in CFU-E
11) Confidence 0.37 Published 2010 Journal J Transl Med Section Body Doc Link PMC2862021 Disease Relevance 0.39 Pain Relevance 0
Overall, increasing NRP1 density, increasing VEGFR2?
Positive_regulation (increasing) of VEGFR2
12) Confidence 0.33 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Possible candidates include: (a) human soluble VEGFR2 (160 kDa) – present in significant quantities in healthy human plasma (7–8 ng/mL) [140] and upregulated in acute myeloid leukemia [39]; (b) soluble NRP1 (90 kDa) – a VEGF165-specific antagonist, with documented renal expression in humans [141], [142]; and (c) cellular fibronectin (?
Positive_regulation (upregulated) of VEGFR2 in plasma associated with leukemia and antagonist
13) Confidence 0.33 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.24 Pain Relevance 0.05
Overall, increasing NRP1 density, increasing VEGFR2?
Positive_regulation (increasing) of VEGFR2
14) Confidence 0.33 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Measured plasma VEGF-A levels tended to increase and VEGFR2 levels to decrease with sunitinib therapy.
Positive_regulation (increase) of VEGFR2 in plasma
15) Confidence 0.30 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727778 Disease Relevance 1.12 Pain Relevance 0.10
Upon activation of VEGFR2 by VEGF, VEGFR2 binds to dimeric PDCD10, translocates to the membrane, and becomes activated.
Positive_regulation (activated) of VEGFR2
16) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2909203 Disease Relevance 0 Pain Relevance 0
As a result of VEGFR2 activation, PI3K is activated and favors the catalysis of PtdIns(3,4)P2 or PIP2 to PtdIns(3,4,5)P3 or PIP3 (Fig 7).
Positive_regulation (activation) of VEGFR2
17) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2909203 Disease Relevance 0 Pain Relevance 0
survival are mediated mainly through binding an activation of the VEGFR-2 [112, 113].
Positive_regulation (activation) of VEGFR-2
18) Confidence 0.16 Published 2008 Journal PPAR Research Section Body Doc Link PMC2490577 Disease Relevance 1.46 Pain Relevance 0.15
In vitro studies with various tumor cell lines have shown that the antiangiogenic effects of sunitinib are mediated through VEGFR and PDGFR.
Positive_regulation (mediated) of VEGFR associated with cancer
19) Confidence 0.13 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721397 Disease Relevance 0.79 Pain Relevance 0.05
VEGFR activation can also trigger intracellular signaling by phosphorylating other proteins such as phospholipase C-?
Positive_regulation (activation) of VEGFR
20) Confidence 0.11 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895781 Disease Relevance 0.41 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox